A Phase II Evaluation of Thalidomide (NSC 66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Thalidomide (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Jan 2013 Primary endpoint amended as reported by ClinicalTrials.gov.
- 02 Nov 2007 Status change from in progress to completed.
- 17 Sep 2005 New trial record.